Ranjan Maity

TL;DR: Hetero-bifunctional small molecules capable of selectively targeting MCL1 using a proteolysis targeting chimera (PROTAC) methodology leading to successful degradation are shown, making these PROTACs a first step toward a new class of antiapoptotic B-cell lymphoma 2 family protein degraders.

TL;DR: A broad immunophenotypic and transcriptomic characterization of the blood and bone marrow T cells of sensitive and resistant MM patients treated with adaptive T cell therapies to identify cellular mediators of resistance to these adoptive immune therapies is performed.

TL;DR: Insight is sought into the mechanisms that promote tumor escape, cause inadequate T-cell stimulation and impaired cytotoxicity in MM and strategies created to escape these multiple immune evasion mechanisms.

TL;DR: A systematic unsupervised interrogation of the bone marrow immune cells of daratumumab and IMiDs treated MM patients is key for the prediction of their clinical responses and the understanding of underlying mechanisms of resistance.

TL;DR: Comparison of the single cell transcriptomes of CD138neg cells from responding patients pre- and post- treatment revealed that Daratumumab and Pomalidomide dramatically modify the immune cells composition (immunome) of the bone marrow niches leading to expansion of effector T cells and depletion of plasmacytoid dendritic cells.